Selected abstracts from the American Diabetes Association's 80th Scientific Sessions discuss when to add injectable therapy, how patients who switched to semaglutide lost more weight and gained glycemic control, and offered results from an early-phase study on a monoclonal antibody that may preserve B-cell function.
During a joint symposium on Saturday, held as part of the 80th American Diabetes Association Scientific Sessions and hosted by JDRF President and CEO Aaron Kowalski, PhD, experts debated the merits and pitfalls of how to measure glycemic control and overall health among persons with diabetes. Which is better, they asked: the traditional measure of glycated hemoglobin or the newer measure, time-in-range?
Yale's Silvio Inzucchi, MD, who has been involved in groundbreaking trials with SGLT2 inhibitors for the past decade, shared data that show patients who did not have type 2 diabetes (T2D) when they started the DAPA-HF trial were 32% less likely to develop the disease if they took dapagliflozin (Farxiga) instead of placebo.
The announcement of a $35 per month out-of-pocket cap for insulin for some individuals with Medicare is a real victory for the American Diabetes Association and for people with diabetes, said Robert Gabbay, MD, PhD, chief medical and scientific officer of the American Diabetes Association.
American women die in childbirth at a higher rate than in any other developed country, while non-Hispanic Black women are more than 3 times more likely to have a maternal death than white women in the United States, according to a review presented at the American Diabetes Association’s 80th Scientific Sessions.
Obesity contributes to development of youth-onset type 2 diabetes (T2D) and can lead to detrimental health outcomes in adulthood. Researchers explored this relationship and offered insights on addressing the problem during a session at the American Diabetes Association’s (ADA) 80th Scientific sessions, held virtually due to coronavirus disease 2019 (COVID-19).
The aim of this feasibility study was to determine whether digital health use via smartphones, a platform that adolescents are more engaged with than other age groups, could aid in teaching youth more about cardiovascular risks, and promote uptake of this knowledge so individuals increase heart healthy behaviors, said Tara Kaushal, MD, physician and clinical researcher at Joslin Diabetes Center.
When it comes to diabetes, lead study author Deepak L. Bhatt, MD, MPH, said clinicians and payers should weigh the considerable costs of what happens when a patient suffers a heart attack or stroke when deciding on a treatment regimen.
In a debate at the American Diabetes Association 80th Scientific Sessions, Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center, will discuss whether sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are ready to be used for primary cardiovascular prevention.
One advantage of conducting an online scientific conference is that more individuals will gain access to information presented at the meeting, said Robert Gabbay, MD, PhD, the newly appointed chief medical and scientific officer of the American Diabetes Association.
Selected technology news briefs from the 79th Scientific Sessions of the American Diabetes Association.
The final morning session of the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California, featured more cardiovascular and renal results from recent trials involving type 2 diabetes drugs.
Oral semaglutide, the first glucagon-like peptide 1 (GLP-1) receptor agonist in a pill, met safety benchmarks and reduced major cardiovascular (CV) events for high-risk patients with type 2 diabetes (T2D) in PIONEER 6, but did not achieve superiority, according to trial results presented at the 79th Scientific Sessions of the American Diabetes Association in San Francisco, California.
The connections among diabetes, cardiovascular (CV) disease, and kidney failure have been a theme of the 79th Scientific Sessions of the American Diabetes Association, which featured a joint session with the American Society of Nephrology.
The observational study will use information from 3 databases to compare the SGLT2 inhibitor to a competing class of therapy for type 2 diabetes. Early cardiovascular and safety data were presented Monday at the 79th Scientific Sessions of the American Diabetes Association.
Findings reported at the 79th Scientific Session of the American Diabetes Association in San Francisco, California, show the type 2 diabetes drug dapagliflozin significantly reduced the risk of renal decline, kidney failure, and renal death.
Results from a study involving adding sitagliptin and increasing doses of metformin for patients who cannot attain glycemic control show that as glycated hemoglobin increases, it becomes harder to reach targets.
Oral semaglutide would be the first non-injectable agent in the GLP-1 receptor agonist class; these drugs produce powerful glycemic control along with weight loss.
Alan Carter, PharmD, principal investigator and senior advisor at MRIGlobal, and adjunct faculty at University of Missouri—Kansas City School of Pharmacy discusses the influence of biosimilars and follow-ons in the insulin market and their reliability should be validated.
Smartphone apps and other new technologies can replace past methods and make life easier for diabetes patients, according to Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine.
Data-sharing capabilities are important for faster communications and results that can greatly benefit the patient, says Robby Booth, senior vice president of research and development at Glytec.
Andrew Rhinehart, MD, chief medical officer at Glytec, discusses the transition from intermediate outcomes in diabetes research of glycemic results to harder outcomes that will benefit the patient financially and through their care.
Patient engagement offers opportunities for shared decision making between visits, when those with diabetes or obesity make choices about food, exercise, or medication that affect health outcomes.
Legislators and Congress need to be pressured to achieve more price transparency in order to manage the high costs on insulin says Alan Carter, PharmD, principal investigator and senior advisor at MRIGlobal, and adjunct faculty at University of Missouri—Kansas City School of Pharmacy.
According to Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine, diabetes management technology is just beginning and can have a positive impact on the daily lives of diabetes patients.
Nina Brown-Ashford, MPH, CHES, deputy group director at the CMS Innovation Center, discusses how Medicare’s Diabetes Prevention Program will help improve population health and contain the high costs of diabetes care.
Material suppliers, manufacturers, pharmacies, and rebate programs all contribute to the rising prices of insulin, according to Alan Carter, PharmD, principal investigator and senior advisor at MRIGlobal, and adjunct faculty at University of Missouri—Kansas City School of Pharmacy.
Diabetes patients will be more satisfied with treatment when they perceive benefits and will continue treatment when physicians keep in contact and point out the progress, says William Polonsky, PhD, CDE, president of the Behavioral Diabetes Institute and associate clinical professor at University of California, San Diego.
Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine addresses the improvements that are needed in the future of closed-loop systems for diabetes treatment.
The move to quality ratings will put more pressure on hospitals to find ways to improve the standard of care while cutting costs.